Literature DB >> 8650075

Identification of endothelin receptors in normal and hyperplasic human prostate tissues.

G Le Brun1, F Moldovan, P Aubin, F Ropiquet, O Cussenot, J Fiet.   

Abstract

Specific endothelin-1 (ET1) binding sites have been demonstrated in membranes derived form normal (NP) and benign hyperplasic (BPH) human prostate using an 125I-ET1 binding assay. 125I saturation experiments and Scatchard analysis demonstrated the existence of a homogeneous population of binding sites with high affinity (Kd(app)) and density (B(max)), respectively, 106 +/- 15 pM and 1086 +/- 399 fmol/mg protein for NP (n = 5) and 168 +/- 26 pM and 964 +/- 445 fmol/mg protein for BPH (n = 5). We demonstrated the presence of two subtypes of ET1 receptors, ETA and ETB, by means of the following ET1 competitors: ET2, ET3, and BQ123 (which is selective for the ETA receptor), and IRL1620 and sarafotoxine c (S6c) (which are selective for the ETB receptor). The displacement curves allowed us to conclude that the large majority (85%) of the ET1 receptors in normal and hyperplasic human prostate are of the A subtype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8650075     DOI: 10.1002/(SICI)1097-0045(199606)28:6<379::AID-PROS7>3.0.CO;2-5

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  3 in total

1.  Pharmacological characterization of endothelin receptor subtypes in the guinea-pig prostate gland.

Authors:  W A Lau; S L Cox; J N Pennefather; F J Mitchelson
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Endothelin-1 inhibits apoptosis in prostate cancer.

Authors:  Joel B Nelson; Michael S Udan; Georgi Guruli; Beth R Pflug
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

3.  Evaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease.

Authors:  Qingchao Meng; Jingmei Li; Mingfeng Li; Rangxue Qiu
Journal:  J Int Med Res       Date:  2021-11       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.